Mylan is the latest manufacturer to get caught up in growing public criticism of drug price hikes, following Valeant andTuring Pharmaceuticals.
and Andrew Pollack covers pharmaceuticals for The New York Times. Gentlemen, welcome. Andrew Pollack, I want to start with you and ask you to explain just basically what's the difference here? What's the big deal between a generic EpiPen and the kind that this company has been producing ...